Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women.
This article describes the results of the first report of bupropion sustained release (SR) in nondepressed females with hypoactive sexual desire disorder (HSDD). Eligible females entered a 4-week, single-blind, placebo baseline phase. Subjects, all of whom did not respond to placebo, continued in a single-blind active treatment phase where they received bupropion SR for up to 8 additional weeks. We assessed HSDD by using investigator ratings of sexual desire and sexual functioning. Of the 51 evaluable subjects who entered the active treatment phase, 29% responded to treatment with bupropion SR. Bupropion SR was generally well tolerated. Pending the results of further study, bupropion SR may offer a treatment option for women with HSDD.
Segraves
R T
RT
Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA. rsegraves@metrohealth.org
Croft
H
H
Kavoussi
R
R
Ascher
J A
JA
Batey
S R
SR
Foster
V J
VJ
Bolden-Watson
C
C
Metz
A
A
D000328:Adult; D000368:Aged; D016642:Bupropion / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010549:Personal Satisfaction; D012720:Severity of Illness Index; D020018:Sexual Dysfunctions, Psychological / Q000175:diagnosis / Q000188:drug therapy*; D016037:Single-Blind Method; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D018492:Dopamine Antagonists; D016642:Bupropion